AJANTA PHARMA
|
|
| BOM : 532331 NSE : AJANTPHARM | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
May 09,2025 |
|
Price(EOD): ₹ 2,540.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 31,725.22 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AJANTA PHARMA | -1.9% | 2% | 4.3% |
| SUN PHARMACEUTICAL INDUSTRIES | -4.9% | 2.1% | 15.5% |
| DIVIS LABORATORIES | -2.2% | 9.3% | 50.5% |
| CIPLA | -4.2% | 4.5% | 4.5% |
| TORRENT PHARMACEUTICALS | -4.4% | -4.5% | 17.2% |
| DR REDDYS LABORATORIES | -1.4% | 4.2% | -8.8% |
| MANKIND PHARMA | -0.1% | -1.5% | 6.6% |
| ZYDUS LIFESCIENCES | -1.6% | 1.3% | -14.6% |
| LUPIN | -2.4% | 3.4% | 19.9% |
FUNDAMENTAL ANALYSIS OF AJANTA PHARMA
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AJANTA PHARMA
[As on : May 09,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
34.47
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 920.39 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] 8.37
P/B Calculated based on Book Value of Rs 3,790.29 Cr
[Latest Year - Mar2025 - Consolidated Results ] 6.83
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,648.10 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
44% 19% 18% |
SHARE PRICE MOMENTUM OF AJANTA PHARMA
AJANTA PHARMA vs SENSEX
DEBT OF AJANTA PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0 0 0 - |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF AJANTA PHARMA
| Pledged Promoter Shares |
12.61 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF AJANTA PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
2.12% -7.38% -12.36% -3.27% |
11.04% 6.77% -3.1% 11.12% |
| QtrlyTrend |
0 | |
| Latest Qtr: Mar2025 | ||
| Quarterly Result Analysis → | ||
AJANTA PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE 150 MIDCAP INDEX | -1.1% | 1.2% | 2.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP150 QUALITY 50 | 0% | 4.1% | 5.9% |
| NIFTY MIDSMALL HEALTHCARE | -0.6% | -1.9% | 18% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | -0.7% | 2.9% | -4.4% |
| NIFTY MIDCAP 150 | -0.7% | 1.9% | 3.6% |
| NIFTY MIDCAP150 MOMENTUM 50 | -0.9% | 2.2% | -2.8% |
You may also like the below Video Courses
FAQ about AJANTA PHARMA
Is AJANTA PHARMA good for long term investment?
As on May 09,2025, the Fundamentals of AJANTA PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AJANTA PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AJANTA PHARMA UnderValued or OverValued?
As on May 09,2025, AJANTA PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of AJANTA PHARMA ?
As on May 09,2025, the Intrinsic Value of AJANTA PHARMA is Rs. 2,135.20 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,761.91
Fair Value [Median EV / Sales Model] : Rs. 2,135.20
Fair Value [Median Price / Sales Model] : Rs. 2,151.82
Estimated Median Fair Value of AJANTA PHARMA : Rs. 2,135.20
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
